NCT00115141已完成2 期
A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 88
- 主要终点
- Clearance of treated wart(s)
研究概览
简要总结
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.
A second purpose is to evaluate the safety of the drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of common warts
- •Two forms of birth control
排除标准
- •Pregnant or breast feeding
- •Other types of warts, ie. plantar
- •Currently participating in another clinical study
- •Chronic viral hepatitis B or C
结局指标
主要结局
Clearance of treated wart(s)
次要结局
- Partial clearance of treated wart(s)
- Wart recurrence
研究者
相似试验
已完成
2 期
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in AdultsWartsNCT00114920Graceway Pharmaceuticals, LLC88
已完成
2 期
Study With a Topical Gel to Treat Common Warts in AdultsWartsNCT00117923Graceway Pharmaceuticals, LLC88
已完成
2 期
Study With a Topical Gel to Treat Common Warts in AdultsWartsNCT00117871Graceway Pharmaceuticals, LLC48
已完成
2 期
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric SubjectsWartsNCT00116675Graceway Pharmaceuticals, LLC84
已完成
2 期
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric SubjectsWartsNCT00116662Graceway Pharmaceuticals, LLC84